ATM and lung carcinoma: Thus, we hypothesized that the combination of small molecule inhibitors targeting ATM with TOP2-targeting medications may not only synergistically suppresses lung cancer cell survival but also attenuate the DNA damage response, thus lowering the possibility of cardiotoxicity and secondary malignancy caused by therapy.